Ignite Creation Date:
2024-05-05 @ 5:12 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00404547
Status:
COMPLETED
Last Update Posted:
2017-02-01
First Post:
2006-11-27
Brief Title:
Asthma Care With Alvesco Ciclesonide in Primary Care in Adults - The ACCEPT-study BY9010CA-102
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
An Open-Label Randomized Multicenter Study in Patients With Asthma to Evaluate the Effectiveness of Alvesco Ciclesonide Compared to Asthma Usual Care in a Primary Practice Setting
Status:
COMPLETED
Status Verified Date:
2016-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to investigate the effectiveness of Alvesco Ciclesonide compared with usual asthma care in the primary care setting Patients with a history of asthma for at least 6 months and who in the opinion of the physician meet the clinical requirements for treatment with inhaled steroids ICS will be enrolled They will either receive Alvesco or usual care
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None